Structure Therapeutics (GPCR) Stock: Buy, Sell, or Hold?
GPCR - Structure Therapeutics Inc. American Depositary Shares
$22.01
-0.87 (-3.80%)
▼
5d:
+0.59%
30d:
-40.37%
90d:
-56.67%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When GPCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GPCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GPCR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GPCR is currently trading at $22.01, which is considered oversold relative to its 30-day fair value range of $24.24 to $36.35.
Technical Outlook: Technically, GPCR is in a strong downtrend. Immediate support is located at $20.73, while resistance sits at $26.80. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: GPCR scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $105.78 (+380.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GPCR is in a strong downtrend. Immediate support is located at $20.73, while resistance sits at $26.80. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: GPCR scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $105.78 (+380.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.24 -
$36.35
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 380.6% below Wall St target ($105.78)
- CAUTION: Bottoming setup, but lagging the sector by 31% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$24.24 -
$36.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$20.73
Resistance Level
$26.80
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.07
Wall Street Target
$105.78
(+380.6%)
Share & Embed Analysis
Last updated: October 22, 2026 6:34 AM ET
Data refreshes hourly during market hours. Next update: 7:34 AM
Data refreshes hourly during market hours. Next update: 7:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GPCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 66 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 73 BUY |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 63 BUY |
